News / Press Release

Research Review: 4 Secrets for Preclinical Success

April 25, 2018

A Q&A with Paul Gonzales of TD2 on the essentials for preclinical success—and what researchers should know going into every project.

Q. What makes a preclinical project successful?

You need a clear understanding of project goals, model systems and variables that could impact study outcomes, but it’s equally important to work with a team that also understands those goals and can execute strategically to ensure the best chance for success.

Q. What should researchers know going into every project? 

You should know the value of your study’s data and how it directly supports your compound’s progress toward the clinic. Each study should move your compound along its development path and take you one step closer to treating patients.

Q. What are some common mistakes that researchers make during preclinical projects?   

Not identifying all the study variables can be the difference between a successful outcome and a failed study. Another common mistake is when researchers latch on to a single indication strategy; instead, maintain an open mind and let the science drive decision-making.

Q. What are some of the top challenges researchers face, and how can they overcome them?

Results from studies performed solely in the originator’s lab can be viewed suspiciously, so it’s critical to have independent third-party confirmation of experimental data. Also, data reproduction is challenging, so work with a team that has a track record of ensuring uncompromised, reproducible data.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: